IgA nephropathy (IgAN) is one of the most common rare immune-related diseases that damages the kidneys' tiny filters, called glomeruli. For many years, treatment options were limited. Today, that is changing. As of August 2026, the U.S. Food and Drug Administration (FDA) has approved six medications specifically for IgAN, with many more being studied in clinical trials. With so many new treatments becoming available, doctors have important questions about how to use these med

IgA nephropathy (IgAN) is entering a period of rapid therapeutic change. In response to the evolving treatment landscape in IgAN, the National Kidney Foundation (NKF) hosted two scientific workshops in spring 2026: The Future of Clinical Trials in IgAN, held April 22-24 in Washington, DC, and B-Cell Therapies for Treating IgAN, held May 14-16 in Dallas, Texas. The Evolving IgAN Treatment Landscape While considered a rare disease, IgAN is the most common primary glomeruloneph

Research on kidney disease has only begun to accelerate with advancements in medical technology, xenotransplantation, and prescription drugs. Kidney disease is a particularly underfunded area of research, with many treatments the same as they were in the 1960s. The proposed OMB rule would be particularly harmful for people with kidney disease whose future requires research advancements in transplantation options and therapy methods. What Is the Proposed OMB Rule? The Office o

The National Kidney Foundation (NKF) recently urged the Centers for Medicare & Medicaid Services (CMS) to strengthen protections for kidney patients in a new Medicaid rule on community engagement reporting requirements. What is Medicaid? Medicaid is a federal and state health insurance program that provides healthcare coverage to eligible people with limited income and certain health needs, including those living with kidney disease, kidney failure, and kidney transplants. It

Dr. Robert Montgomery, Director of the NYU Langone Transplant Institute, presenting at the 2024 Spring Clinical Meetings Xenotransplant Session. The Second Annual Richard Slayman Clinical Xenotransplantation Workshop is a groundbreaking kidney transplant meeting that brought together experts to discuss the future of xenotransplantation, including the National Kidney Foundation's own Heather Murphy, who represented the patient perspective. What is Xenotransplantation? Xenotra